These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22507962)

  • 1. The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.
    Furet P; Chène P; De Pover A; Valat TS; Lisztwan JH; Kallen J; Masuya K
    Bioorg Med Chem Lett; 2012 May; 22(10):3498-502. PubMed ID: 22507962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
    Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
    Furet P; Masuya K; Kallen J; Stachyra-Valat T; Ruetz S; Guagnano V; Holzer P; Mah R; Stutz S; Vaupel A; Chène P; Jeay S; Schlapbach A
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4837-4841. PubMed ID: 27542305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
    ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
    Patil SP
    Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 inhibitors for cancer therapy.
    Vassilev LT
    Trends Mol Med; 2007 Jan; 13(1):23-31. PubMed ID: 17126603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y; Aguilar A; Bernard D; Wang S
    J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.
    Miyazaki M; Naito H; Sugimoto Y; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
    Bioorg Med Chem Lett; 2013 Feb; 23(3):728-32. PubMed ID: 23266121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.